Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ANRO vs OKYO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANRO Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 4–1 Matrix Metrics)

ANRO Overall Winner 6-Pillar Tally: ANRO 3 – 1 OKYO (2 Tie) Matrix Metrics: ANRO 4 – 1 OKYO

As of Nov 20, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over OKYO Pharma Limited (OKYO) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ANRO carries a Unified Composite Score of 45.8/100 (HOLD) at $25.37 (N/M Forward P/E, 0.0% operating margin), whereas OKYO carries 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ANRO is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.5); meanwhile OKYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANRO vs OKYO
ANRO NYSE Head-to-Head Winner
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.37
-4.3% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.86β · 91% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.9%) with fading momentum, RSI 49
RSI-14: 48.5 · SMA20: $25.37 · SMA50: $25.58
OKYO NASDAQ
OKYO Pharma Limited Ordinary Shares
Biological Products, (No Diagnostic Substances)
$1.07
-7.76% 1D
Market Cap $62.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 76% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 50.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 32
RSI-14: 31.8 · SMA20: $1.35 · SMA50: $1.38

6-Pillar Scorecard Institutional Category Breakdown (ANRO 3 – 1 OKYO)

Columns: Metric · ANRO · OKYO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ANRO
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $1.1B $62.7M
3. Profitability & Quality ANRO
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -46.7% -263.8%
4. Balance Sheet & Cash Flow ANRO
Cash Generation (TTM) -$80M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $301M Net Cash $0.23 Book/Sh · -263.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OKYO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 80.4% (8th %ile) N/A (N/A)
Put/Call OI Skew 20.60x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANRO (4) vs OKYO (1)
Institutional Metric ANRO OKYO Criterion Row Edge
Market Capitalization
Scale
$1.1B $62.7M Larger Scale ANRO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-46.7% -263.8% Higher ROE ANRO
52-Week Range Position
Momentum
52% ($13–$37) 3% ($1–$3) Stronger Trend ANRO
Beta / 30D Volatility
Risk Regime
1.86β · 91% Vol 1.05β · 76% Vol Lower Realized Risk OKYO
Unified Institutional Score
Composite Signal
45.8 / 100 (HOLD) 42.8 / 100 (HOLD) Higher Composite ANRO
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$80M ($301M Net Cash) N/A ($0.23 Book/Sh · -263.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANRO +41.49 pp
ANRO: +14.28% · OKYO: -27.21%
3M Horizon OKYO +1.34 pp
ANRO: -30.01% · OKYO: -28.67%
6M Horizon ANRO +53.92 pp
ANRO: +19.56% · OKYO: -34.36%
1Y Horizon ANRO +110.29 pp
ANRO: +63.26% · OKYO: -47.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs OKYO. Trailing 12-month operating profitability (ANRO 0.0% vs OKYO 0.0%) and valuation multiples (ANRO N/M vs OKYO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M
OKYO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-263.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANRO BREAKDOWN
61d in phase · OBV DISTRIBUTION
Current IV 80.4%
IV Percentile 8th %ile
Put/Call OI Skew 20.60x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OKYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OKYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OKYO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANRO vs OKYO Key Questions & Quantitative Answers

As of Nov 20, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over OKYO Pharma Limited (OKYO) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ANRO carries a Unified Composite Score of 45.8/100 (HOLD) at $25.37 (N/M Forward P/E, 0.0% operating margin), whereas OKYO carries 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ANRO is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.5); meanwhile OKYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANRO leads the Growth & Scale pillar: ANRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with OKYO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ANRO generates N/A in USD-normalized revenue versus N/A for OKYO. In operating R&D and SG&A reinvestment, ANRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OKYO.

ANRO and OKYO trade at balanced relative valuation multiples. ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas OKYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANRO (-46.7% ROE) versus OKYO (-263.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ANRO carries 80.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 20.60x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.86β · 91% Vol realized risk). By comparison, OKYO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.